Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.
Vigene Biosciences Inc.’s has opened its new research facility in Rockville.
The opening of a new laboratory at 5 Research Court — near Interstate-270’s Shady Grove Road exit — significantly increases the biotech’s Rockville footprint, adding 51,000 square feet to its existing 20,000 square feet at a separate facility nearby. The project cost more than $20 million, according to Vigene.
Register Now for the 6th Annual BioHealth Capital Region (BHCR) Forum held on April 14-15 at AstraZeneca in Gaithersburg, MD. Join your peers biotech and life science executives and expert speakers from industry, academia, healthcare, government, finance and real estate development, among others, converged to discuss the BHCR’s path forward to becoming a top three U.S. biotech cluster by 2023.
Register Now for the 6th Annual BioHealth Capital Region (BHCR) Forum held on April 14-15 at AstraZeneca in Gaithersburg, MD. Join your peers biotech and life science executives and expert speakers from industry, academia, healthcare, government, finance and real estate development, among others, converged to discuss the BHCR’s path forward to becoming a top three U.S. biotech cluster by 2023.
Here’s a list of our upcoming events. Get them on your calendar so you don’t miss anything.
Here’s a list of our upcoming events. Get them on your calendar so you don’t miss anything.
Submit your application for a change to be named the Startup Company with the Most Commectial Potential at the BHCR Forum, win $10,000 and more!
Here’s a list of our upcoming events. Get them on your calendar so you don’t miss anything.
When a Canadian company called Deep Genomics announced in September that it had used artificial intelligence to solve a long-standing mystery about a genetic disorder called Wilson’s disease—and, what’s more, had used another deep-learning platform to identify a potential treatment—there was a flurry of excitement in the drug development world. The apparent milestone, which the company hailed as the “first-ever A.I.- discovered therapeutic candidate,” got echoing headlines from dozens of news outlets, and in January, the five-year-old startup received a $40 million endorsement in the form of a fresh round of venture capital funding.
Image: JAMIE CHUNG—TRUNK ARCHIVE – https://fortune.com
Patient concierge startup HelpAround has nabbed $6 million to help people with chronic diseases stick with their treatment.
The Bethesda company, whose mobile platform connects patients with resources for the drugs they’re prescribed, is pushing deeper into the specialty pharmacy arena — where medications are high-cost and complex — after focusing first on the diabetes and renal disease space. The business is now partnering with these drug manufacturers to keep patients from dropping out of their treatment plans, especially those who have been newly diagnosed.
Image: Yishai Knobel is co-founder and CEO of HelpAround. HELPAROUND
